跳轉至內容
Merck

Gut/brain axis and the microbiota.

The Journal of clinical investigation (2015-02-18)
Emeran A Mayer, Kirsten Tillisch, Arpana Gupta
摘要

Tremendous progress has been made in characterizing the bidirectional interactions between the central nervous system, the enteric nervous system, and the gastrointestinal tract. A series of provocative preclinical studies have suggested a prominent role for the gut microbiota in these gut-brain interactions. Based on studies using rodents raised in a germ-free environment, the gut microbiota appears to influence the development of emotional behavior, stress- and pain-modulation systems, and brain neurotransmitter systems. Additionally, microbiota perturbations by probiotics and antibiotics exert modulatory effects on some of these measures in adult animals. Current evidence suggests that multiple mechanisms, including endocrine and neurocrine pathways, may be involved in gut microbiota-to-brain signaling and that the brain can in turn alter microbial composition and behavior via the autonomic nervous system. Limited information is available on how these findings may translate to healthy humans or to disease states involving the brain or the gut/brain axis. Future research needs to focus on confirming that the rodent findings are translatable to human physiology and to diseases such as irritable bowel syndrome, autism, anxiety, depression, and Parkinson's disease.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
4-羟基苯甲酸丁酯, ≥99.0% (GC)
Supelco
对羟基苯甲酸丁酯, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
4-羟基苯甲酸丁酯, ≥99%
USP
对羟基苯甲酸丁酯, United States Pharmacopeia (USP) Reference Standard
对羟基苯甲酸丁酯, European Pharmacopoeia (EP) Reference Standard